Abstract
Context: The dengue virus continues to pose a serious global health challenge due to the absence of effective antiviral therapies. Non-structural protein 5 (NS5), a multifunctional non-structural protein containing methyltransferase and RNA-dependent RNA polymerase domains, is essential for viral replication and represents a high-priority therapeutic target. In this study, potential inhibitors targeting two functional sites of Dengue virus serotype 3 (DENV-3) NS5 were identified through structure-based virtual screening and structural dynamics analysis. Docking results identified PubChem compound 135,625,223 as the strongest binder at the RNA-binding site with a binding affinity of − 11.8 kcal/mol, forming a hydrogen bond with Arg481 and a hydrophobic interaction with Phe485. Molecular dynamics simulations showed that the S-adenosylmethionine (SAM)-binding site ligand formed a more stable complex with lower root-mean-square deviation (RMSD) (0.26 nm) and reduced flexibility, indicating a promising lead candidate for further optimization and experimental validation against dengue virus NS5. Methods: The full-length NS5 structure was constructed using homology modeling with MODELLER, ab initio modeling, and AlphaFold, and the best model was selected based on low RMSD and stereochemical quality. A library of 587 antiviral compounds retrieved from PubChem was docked against the SAM-binding site of the methyltransferase domain and the RNA-binding site of the polymerase domain using AutoDock Vina. The top-ranked ligands were further evaluated through Insilico screening and 300-ns molecular dynamics simulations using GROMACS.
| Original language | English |
|---|---|
| Article number | 263 |
| Journal | Journal of Molecular Modeling |
| Volume | 32 |
| Issue number | 8 |
| DOIs | |
| Publication status | Published - 8 Jul 2026 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Dengue virus NS5
- Dual-site inhibitors
- Molecular dynamics
- Structure-based drug discovery
- Virtual screening
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver